Floatz logo

Pvx-410

Metastatic Triple-Negative Breast Carcinoma

OncoPep, Inc.vaccinePhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

447 Active assets in the Metastatic Triple-Negative Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Capivasertib
AstraZeneca
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Famitinib
Fudan University
Phase 3BB

View all 50 →

Same molecule, other indications

Pvx-410 is also rated in:

smoldering plasma cell myelomaDormant
CC
Indicative ·
44 / 100
View asset →
breast cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →